DANIEL BRADBURY

Daniel Bradbury stands as a highly respected figure in the life sciences investment landscape, currently serving as a Managing Partner at BioBrit LLC. BioBrit is a private investment firm dedicated to fostering innovation within the biotechnology, pharmaceutical, and medical technology sectors. In his role, Mr. Bradbury leverages his extensive operational and strategic expertise to identify promising early-stage and growth-stage companies that have the potential to significantly impact patient care and global health.

Mr. Bradbury's investment focus areas are deeply rooted in his profound understanding of the life sciences industry. He targets companies developing novel therapeutics, advanced diagnostics, and innovative medical devices. His keen eye for disruptive technologies and strong management teams allows BioBrit to make strategic investments that drive scientific progress and generate substantial value. He is particularly interested in areas with high unmet medical needs, where cutting-edge research can translate into transformative treatments.

Before his tenure at BioBrit, Daniel Bradbury built an illustrious career marked by significant leadership roles in major pharmaceutical and biotechnology companies. Most notably, he served as President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases. Under his leadership, Amylin developed and commercialized important therapies, ultimately leading to its acquisition by Bristol-Myers Squibb and AstraZeneca. Prior to Amylin, he held senior executive positions at Allergan, Inc., and other prominent healthcare firms, where he was instrumental in product development, commercialization, and strategic growth initiatives. His career journey reflects a consistent commitment to advancing medical science and bringing life-changing medicines to patients worldwide.

While specific individual investments by Daniel Bradbury through BioBrit are typically private, his involvement with various public and private company boards often signals his strategic influence and investment interests. He has served on the boards of directors for companies such as Geron Corporation, Intercept Pharmaceuticals, and others, indicating his continued engagement with companies at the forefront of medical innovation. His deep industry network and proven track record make him a sought-after advisor and investor in the competitive life sciences arena. Through BioBrit LLC, Daniel Bradbury continues to shape the future of healthcare by backing the next generation of groundbreaking biotech and pharma ventures.